Research analysts at Goldman Sachs (NYSE: GS) increased their price target on shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to $48.00 in a report issued on Thursday.Separately, analysts at Jefferies Group (NYSE: JEF) reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Friday, December 23rd. They now have a $43.00 price target on the stock. Analysts at Piper Jaffray (NYSE: PJC) reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Thursday, December 22nd. They now have a $45.00 price target on the stock. Also, analysts at Needham & Company reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Thursday, December 22nd.Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business provides vertical integration to Teva’s own pharmaceutical production. The Company’s global operations are conducted from North and Latin America to Europe and Asia. As December 31, 2010, it had direct operations in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites in 19 countries, 28 pharmaceutical research and development (R&D) centers and 21 API manufacturing sites. On October 14, 2011, it acquired Cephalon, Inc.Teva Pharmaceutical Industries Ltd traded down 1.39% on Thursday, hitting $45.45. Teva Pharmaceutical Industries Ltd has a 1-year low of $35.00 and a 1-year high of $56.34. The stock has a 50-day moving average of $42. and a 200-day moving average of $40.99. The company has a market cap of $40.223 billion and a price-to-earnings ratio of 13.72.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment